Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2015, Article ID 975695, 7 pages
http://dx.doi.org/10.1155/2015/975695
Research Article

HOMA, BMI, and Serum Leptin Levels Variations during Antiviral Treatment Suggest Virus-Related Insulin Resistance in Noncirrhotic, Nonobese, and Nondiabetic Chronic Hepatitis C Genotype 1 Patients

1Gastroenterology Unit, San Paolo Hospital, Via Genova 38, 17100 Savona, Italy
2Department of Endocrinology, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, Italy
3Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, Italy

Received 14 December 2014; Accepted 4 February 2015

Academic Editor: Roberto César P. Lima-Júnior

Copyright © 2015 Alessandro Grasso et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. P. Manns, J. G. McHutchison, S. C. Gordon et al., “Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial,” The Lancet, vol. 358, no. 9286, pp. 958–965, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. M. W. Fried, M. L. Shiffman, K. R. Reddy et al., “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection,” The New England Journal of Medicine, vol. 347, no. 13, pp. 975–982, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. S. J. Hadziyannis, H. Sette Jr., T. R. Morgan et al., “Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose,” Annals of Internal Medicine, vol. 140, no. 5, pp. 346–355, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Kau, J. Vermehren, and C. Sarrazin, “Treatment predictors of a sustained virologic response in hepatitis B and C,” Journal of Hepatology, vol. 49, no. 4, pp. 634–651, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Ferenci, “Predictors of response to therapy for chronic hepatitis C,” Seminars in Liver Disease, vol. 24, no. 2, pp. 25–31, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. M. L. Shiffman, R. T. Chung, and F. M. Hamzeh, “Time to HCV RNA undetectability supersedes baseline factors in predicting SVR in patients with HCV genotype 1,” Journal of Hepatology, vol. 48, supplement 2, p. S313, 2008. View at Publisher · View at Google Scholar
  7. A. J. Thompson, A. J. Muir, M. S. Sulkowski et al., “Interleukin-28b polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus,” Gastroenterology, vol. 139, no. 1, pp. 120–e18, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Shintani, H. Fujie, H. Miyoshi et al., “Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance,” Gastroenterology, vol. 126, no. 3, pp. 840–848, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Kawaguchi, T. Yoshida, M. Harada et al., “Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3,” American Journal of Pathology, vol. 165, no. 5, pp. 1499–1508, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Muzzi, G. Leandro, L. Rubbia-Brandt et al., “Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients,” Journal of Hepatology, vol. 42, no. 1, pp. 41–46, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Delgado-Borrego, S. H. Jordan, B. Negre et al., “Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial,” Clinical Gastroenterology and Hepatology, vol. 8, no. 5, pp. 458–462, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. A. J. Thompson, K. Patel, W.-L. Chuang et al., “Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3,” Gut, vol. 61, no. 1, pp. 128–134, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Bortoletto, L. Scribano, S. Realdon et al., “Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance,” Journal of Viral Hepatitis, vol. 17, no. 7, pp. 475–480, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Romero-Gómez, M. Del Mar Viloria, R. J. Andrade et al., “Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients,” Gastroenterology, vol. 128, no. 3, pp. 636–641, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. H. S. Conjeevaram, A. S. Wahed, N. Afdhal, C. D. Howell, J. E. Everhart, and J. H. Hoofnagle, “Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C,” Gastroenterology, vol. 140, no. 2, pp. 469–477, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Tsochatzis, G. V. Papatheodoridis, and A. J. Archimandritis, “The evolving role of leptin and adiponectin in chronic liver diseases,” The American Journal of Gastroenterology, vol. 101, no. 11, pp. 2629–2640, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. O. Lo Iacono, G. Venezia, S. Petta et al., “The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C,” Alimentary Pharmacology and Therapeutics, vol. 25, no. 10, pp. 1181–1191, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. K. G. Ishak, “Chronic hepatitis: morphology and nomenclature,” Modern Pathology, vol. 7, no. 6, pp. 690–713, 1994. View at Google Scholar · View at Scopus
  19. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Ikeda, T. Suehiro, T. Nakamura, Y. Kumon, and K. Hashimoto, “Clinical significance of the insulin resistance index as assessed by homeostasis model assessment,” Endocrine Journal, vol. 48, no. 1, pp. 81–86, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Fartoux, A. Poujol-Robert, J. Guéchot, D. Wendum, R. Poupon, and L. Serfaty, “Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C,” Gut, vol. 54, no. 7, pp. 1003–1008, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Kawaguchi, T. Ide, E. Taniguchi et al., “Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2,” The American Journal of Gastroenterology, vol. 102, no. 3, pp. 570–576, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Deltenre, A. Louvet, M. Lemoine et al., “Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis,” Journal of Hepatology, vol. 55, no. 6, pp. 1187–1194, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Eslam, R. Aparcero, T. Kawaguchi et al., “Meta-analysis: insulin resistance and sustained virological response in hepatitis C,” Alimentary Pharmacology and Therapeutics, vol. 34, no. 3, pp. 297–305, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Fattovich, G. Svegliati Baroni, M. Pasino et al., “Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome,” Digestive and Liver Disease, vol. 44, no. 5, pp. 419–425, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Grasso, F. Malfatti, P. D. Leo et al., “Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin,” Journal of Hepatology, vol. 51, no. 6, pp. 984–990, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Fattovich, L. Covolo, M. Pasino et al., “The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients,” Liver International, vol. 31, no. 1, pp. 66–74, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Khattab, M. Eslam, M. A. Sharwae, M. Shatat, A. Ali, and L. Hamdy, “Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients,” The American Journal of Gastroenterology, vol. 105, no. 9, pp. 1970–1977, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Persico, M. Capasso, E. Persico et al., “Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy,” Hepatology, vol. 46, no. 4, pp. 1009–1015, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Romero-Gómez, M. Diago, R. J. Andrade et al., “Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin,” Hepatology, vol. 50, no. 6, pp. 1702–1708, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. H. M. Elgouhari, K. B. Cesario, R. Lopez, and N. N. Zein, “Pioglitazone improves early virologic kinetic response to PEGIFN/RBV combination therapy in hepatitis C genotype 1 naïve patients,” Hepatology, vol. 48, supplement, p. 383A, 2008. View at Google Scholar
  32. S. A. Harrison, F. Hamzeh, J. Han, and J. M. Vierling, “Efficacy, safety, and metabolic effects in chronic hepatitis C (CHC) genotype 1 (G1) patients with insulin resistance (IR) treated with pioglitazone (PIO) and peginterferon alfa-2a plus ribavirin (P/R),” Hepatology, vol. 54, no. S1, p. 439A, 2011. View at Google Scholar
  33. F. Marra and C. Bertolani, “Adipokines in liver diseases,” Hepatology, vol. 50, no. 3, pp. 957–969, 2009. View at Publisher · View at Google Scholar · View at Scopus